Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693793 | 0.84 | GRM5 (0.42) | TTRALBCYP2A6GRM5EGLN2 | |
| SCHEMBL2160632 | 0.84 | GRM5 (0.42) | TTRALBCYP2A6GRM5EGLN2 | |
| SCHEMBL7358317 | 0.84 | NOS1 (0.39) | TTRALBCYP2A6ALDH1A1IDH1 | |
| SCHEMBL22477339 | 0.81 | CYP2A6 (0.39) | TTRALBCYP2A6ALDH1A1IDH1 | |
| SCHEMBL11982666 | 0.81 | CYP2A6 (0.50) | TTRALBCYP2A6ALDH1A1IDH1 | |
| SCHEMBL5898258 | 0.79 | TTR (0.39) | TTRALBCYP2A6ALDH1A1IDH1 | |
| SCHEMBL6742065 | 0.79 | CYP2A6 (0.38) | TTRALBCYP2A6ALDH1A1IDH1 | |
| SCHEMBL16952693 | 0.79 | CYP2A6 (0.48) | TTRALBCYP2A6GRM5EGLN2 | |
| SCHEMBL501516 | 0.79 | CYP2A6 (0.38) | TTRALBCYP2A6ALDH1A1IDH1 | |
| SCHEMBL7896912 | 0.79 | LOXL2 (0.48) | TTRALBCYP2A6ALDH1A1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | PFIZER INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170233390-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-9670201-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2016046755-A1 | METHYL-AND TRIFLUOROMETHYL-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160090381-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER (US) | 2016-03-31 | — | — | US | disclosed |
| CN-104968656-A | AUTOTAXIN INHIBITORS | NOVARTIS AG | 2015-10-07 | — | — | CN | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| WO-2003055856-A2 | BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-10 | — | — | WO | disclosed |
| EP-1299379-A2 | LACTAM METALLOPROTEASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-6495548-B1 | SUCH AS 3-((2,2-DIMETHYL-1-OXOPROPYL)AMINO)-N-HYDROXY-1-(4-((2-METHYL-4 -QUINOLINYL)METHOXY)PHENYL)-2-OXO-3-PYRROLIDINE ACETAMIDE; PREVENTING UNCONTROLLED BREAKDOWN OF CONNECTIVE TISSUE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6455522-B1 | ANTIINFLAMMATORY AGENTS; AGGRECANASE AND TUMOR NECROSIS FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| WO-2002004416-A2 | LACTAM METALLOPROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | RORC, RORB, RORA | TTR 1838/4885ALB 3183/4885CYP2A6 1250/4885 |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | TTR 3239/4885ALB 3999/4885CYP2A6 1068/4885 |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | RORC, RORB, RORA | TTR 2599/4885ALB 3635/4885CYP2A6 667/4885 |
| US-20170233390-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | TTR 3239/4885ALB 3999/4885CYP2A6 1068/4885 |
| US-20160090381-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | TTR 3239/4885ALB 3999/4885CYP2A6 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.